Tiotropium in asthma poorly controlled with standard combination therapy

Area of Science:

• Respiratory Medicine
• Clinical Pharmacology
• Pulmonology

Background:

• Many asthma patients experience frequent exacerbations and persistent airflow obstruction despite standard inhaled glucocorticoid and long-acting beta-agonist (LABA) therapy.
• Identifying effective add-on treatments is crucial for managing poorly controlled asthma.

Purpose of the Study:

• To evaluate the efficacy of adding tiotropium to inhaled glucocorticoids and LABAs in patients with symptomatic, poorly controlled asthma.
• To assess the impact on lung function and the frequency of severe asthma exacerbations.

Main Methods:

• Two replicate, randomized, controlled trials were conducted with 912 patients receiving inhaled glucocorticoids and LABAs.
• Patients were randomized to receive either tiotropium (5 μg once daily) or placebo via a soft-mist inhaler for 48 weeks.
• Inclusion criteria included symptomatic asthma, post-bronchodilator FEV(1) ≤80% predicted, and a history of at least one severe exacerbation in the prior year.

Main Results:

• The addition of tiotropium resulted in a significant improvement in peak and trough FEV(1) at 24 weeks compared to placebo.
• Tiotropium increased the time to the first severe exacerbation (282 days vs. 226 days) and reduced the overall risk by 21% (P=0.03).
• Adverse events were similar between the tiotropium and placebo groups, with no reported deaths.

Conclusions:

• Adding tiotropium to inhaled glucocorticoids and LABAs is an effective strategy for patients with poorly controlled asthma.
• The treatment provides modest sustained bronchodilation and significantly reduces the risk of severe exacerbations.
• Tiotropium represents a safe and beneficial add-on therapy for this patient population.